Active — Not RecruitingNot Applicable

Fibroscan Study in HCC

Hong Kong207 participantsStarted 2013-02-27

Plain-language summary

In patients with HCC undergoing therapy 1. We aim to determine the prognostic significance of liver stiffness in patients with HCC 2. We aim to determine the rate and severity of complications of treatment and its association with liver stiffness in patients with HCC

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. For TACE cohort, patients undergoing first cycle TACE are eligible.
✓. For systemic therapy cohort, patients undergoing first-line systemic therapy are eligible.
✓. For surgery cohort, patient undergoing surgery are eligible.

What they're measuring

Overall survival

Timeframe: 3 years

Trial details

NCT IDNCT01796145

SponsorChinese University of Hong Kong

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2026-12-31

View on ClinicalTrials.gov More Confirmed Diagnosis of Hepatocellular Carcinoma trials